EGFR Mutations

Somatic gain-of-function mutations in exons encoding the epidermal growth factor receptor (EGFR) tyrosine kinase domain are found in about 10% of non-small cell lung cancers (NSCLCs) from the USA with higher percentages observed in east Asia. EGFR mutations are strong determinants of tumour response to EGFR tyrosine kinase inhibitors in non-small-cell lung cancer (NSCLC). Lung Adenocarcinomas from patients who respond to the tyrosine kinase inhibitors Gefitinib (Iressa) or Erlotinib (Tarceva) usually harbour somatic gain-of-function mutations in exons encoding the kinase domain of the EGFR.
Reference range: 


Sample type and Volume required: 
Paraffin embeded curls/fresh tissue
Turnaround time: 
5 days
Storage and transport: 
Room temperature
Molecular Oncology Unit at Guy's
0207 188 1716
Genetics Department
Southwark Wing - 4th Floor
Guy's Hospital
Great Maze Pond
London SE1 9RT

For clinical advice or interpretation of results, please contact the laboratory in the first instance.

Print as a PDF

Last updated: 19/06/2018